InCrowd Novel Coronavirus (COVID-19) Vaccine Development – Wave 2

Given the recent uptick in COVID-19 cases in the US, many InCrowd panelists have been reporting that they do not expect things to return to normal until a vaccine is developed and disseminated. In order to deepen our understanding of the COVID-19 vaccine landscape, we surveyed infectious disease specialists across the country to get their perception and predictions on the efficacy, impact, and competitive landscape of COVID-19 vaccines.*

* Please note, views in this survey reflect opinions only as reported by responding physicians.

Methodology:

• Method:
  • 12-Minute MicroSurvey via InCrowd
• Crowds:
  • Infectious disease doctors
• Sample Size:
  • n = 100
    • Community Hospital, Academic Hospital, Office-based
• Fielding Period:
  • October 22nd – 26th

InCrowd’s other COVID-19 Tracking Reports:

• Telemedicine & Remote-Patient Monitoring Report
• Physician Tracking Report – Wave 6
• Non-Frontline Specialist Tracking Report – Wave 2
• Patient Tracking Report – Wave 3
• Treatment & Outcomes of Diabetes Patients During the COVID-19 Pandemic